Short answer
Xeris Biopharma Holdings, Inc. (XERS) filed an 8-K current report with the SEC on August 6, 2026 reporting Item EX-99.1 (Exhibit EX-99.1), Item 2.02 (Results of Operations and Financial Condition). Q2 and first-half 2026 operating results and business highlights announced.
Xeris Biopharma Holdings, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q2 and first-half 2026 operating results and business highlights announced
- Results cover three and six months ended June 30, 2026
- Full financial details and management commentary in Exhibit 99.1 press release
Item EX-99.1 · Exhibit EX-99.1
- Q2 revenue $92.1M, up 29%, led by Recorlev revenue $56.8M, up 81%
- Net product revenue $91.0M, up 34%, with gross margin improving to 86% from 82%
- Adjusted EBITDA $19.3M versus $12.5M, despite SG&A rising 37% to support Recorlev expansion
- GAAP net loss $31.1M, driven by a one-time non-cash $31M charge tied to 2028 Convertible Notes exchanges
- Full-year 2026 revenue guidance tightened to $385M-$390M; all 2028 Convertible Notes eliminated, but approximately 8.6M shares issued in July
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Xeris Biopharma Holdings, Inc. 8-K filings
Get the next XERS 8-K as it lands
Follow XERS for push alerts, or ask the research agent what this filing means.